Xu Ruida, Liu Shuzhong, Chen Haihong, Lao Lifeng
Department of Orthopaedic Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, P.R. China.
Oncol Rep. 2016 Mar;35(3):1757-63. doi: 10.3892/or.2015.4497. Epub 2015 Dec 18.
Autophagy has been recognized as an important element of tumor cell migration, invasion, and chemo-resistance, and our previous results showed that Beclin-1-mediated autophagy contributed to osteosarcoma chemoresistance. However, the regulating mechanism of autophagy is still unclear. In this study, our aim was to clarify microRNA (miRNA)-related mechanisms underlying Beclin-1-mediated autophagy followed by chemotherapy in osteosarcoma. First, miRNA screening using qRT-PCR identified that miR-30a was significantly reduced in Dox-resistant osteosarcoma cells. Second, the autophagy activity in Dox-resistant increased while miR-30a expression reduced after chemotherapy agents as indicated by the enhanced expression of Beclin-1, the increased conversion of microtubule-associated protein LC3-I to LC3-II. Furthermore, overexpression of miR-30a significantly promoted chemotherapy-induced apoptosis and reduced autophagy activity responding to chemotherapy. Moreover, rapamycin, an autophagy promoter was able to partly reverse the effect of miR-30a and Luciferase reporter assay identified that miR-30a directly binds to the 3'-UTR of Beclin-1 gene, which further confirmed that miR-30a reduced chemoresistance via suppressing Beclin-1-mediated autophagy. Collectively these results indicate miR-30a and its downstream target gene Beclin-1 can be used in treatment of osteosarcoma chemo-resistance in the future.
自噬已被认为是肿瘤细胞迁移、侵袭和化疗耐药的一个重要因素,我们之前的结果表明,Beclin-1介导的自噬促成骨肉瘤的化疗耐药。然而,自噬的调控机制仍不清楚。在本研究中,我们的目的是阐明骨肉瘤中Beclin-1介导的自噬及后续化疗相关的微小RNA(miRNA)机制。首先,使用qRT-PCR进行miRNA筛选,结果显示耐多柔比星骨肉瘤细胞中miR-30a显著降低。其次,化疗药物处理后,耐多柔比星细胞中的自噬活性增加,而miR-30a表达降低,这表现为Beclin-1表达增强、微管相关蛋白LC3-I向LC3-II的转化增加。此外,miR-30a过表达显著促进化疗诱导的凋亡,并降低对化疗的自噬活性。而且,自噬促进剂雷帕霉素能够部分逆转miR-30a的作用,荧光素酶报告基因检测确定miR-30a直接与Beclin-1基因的3'-UTR结合,这进一步证实miR-30a通过抑制Beclin-1介导的自噬降低化疗耐药性。总体而言,这些结果表明miR-30a及其下游靶基因Beclin-1未来可用于治疗骨肉瘤的化疗耐药。